Register to view the archived recording here.
Silence Says New Patents Key to Licensing Deals, Keeps Eye on R&D Collaborations
As RNAi drug candidates move through pipelines and information about their structures becomes available, Silence expects to find that "a number" of them incorporate modifications covered by its IP.
New to GenomeWeb? Register here quickly.